Biophan signs letter of intent for MRI-enabled stent technology:
This article was originally published in Clinica
Executive Summary
Biophan has signed a letter of intent with two German biomedical researchers for a worldwide exclusive licence to a cardiovascular stent technology that enables MRI angiography of the interior of vascular stents. Developed by Drs Arno Bucker and Alexander Ruebben through the University of Aachen, the alloy metal-based technology adds to Biophan's current portfolio of resonant circuit technologies for making stents MRI-visible. The Rochester, New York firm said that conventional metallic stents prevent the use of MRI angiography due the "Faraday cage effect" - a process whereby electric charge sits on the outer surface of a conductor. The company also has the option to sub-license the technology to third parties.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.